• Latest
  • Trending
  • All
  • News
  • Business
  • Lifestyle
Merck Anti-COVID Pill Will Not Be Added to India's National Treatment Protocol

Merck Anti-COVID Pill Will Not Be Added to India's National Treatment Protocol

January 9, 2022
EXCLUSIVE: Top House Committee Digs Into Orgs That Turbocharged Biden Border Crisis

EXCLUSIVE: Top House Committee Digs Into Orgs That Turbocharged Biden Border Crisis

July 15, 2025
EXCLUSIVE: Rep. Andy Barr Wants To Turn Off Taxpayer Money Tap For Schools That Defy Trump’s EO On Women’s Sports

EXCLUSIVE: Rep. Andy Barr Wants To Turn Off Taxpayer Money Tap For Schools That Defy Trump’s EO On Women’s Sports

July 15, 2025
Just One Republican On House Rules Panel Votes To Release Epstein Files

Just One Republican On House Rules Panel Votes To Release Epstein Files

July 15, 2025
GORDON CHANG: Will Xi Jinping Attack America To Prevent His Political Demise?

GORDON CHANG: Will Xi Jinping Attack America To Prevent His Political Demise?

July 15, 2025
EXCLUSIVE: Trump’s Energy Agenda Can Help US Beat China In Crucial Tech Race, Oil Industry Leader Says

EXCLUSIVE: Trump’s Energy Agenda Can Help US Beat China In Crucial Tech Race, Oil Industry Leader Says

July 14, 2025
Lefty Groups Biden Showered In Taxpayer Cash Coaching Illegals To Evade ICE

Lefty Groups Biden Showered In Taxpayer Cash Coaching Illegals To Evade ICE

July 14, 2025
Senate Confirms Trump’s First Judicial Pick To Replace Obama Appointee

Senate Confirms Trump’s First Judicial Pick To Replace Obama Appointee

July 14, 2025
‘Am I Going To Lose My F***ing Rights?’: Shawn Ryan Tells Newsom How Gun Laws Can Hurt Combat Vets

‘Am I Going To Lose My F***ing Rights?’: Shawn Ryan Tells Newsom How Gun Laws Can Hurt Combat Vets

July 14, 2025
‘In It To Win It’: Andrew Cuomo To Stay In NYC Mayor Race Despite Primary Defeat

‘In It To Win It’: Andrew Cuomo To Stay In NYC Mayor Race Despite Primary Defeat

July 14, 2025
Mike Johnson Tells Senate To Think Twice Before Weakening $9.4 Billion Rescissions Package

Mike Johnson Tells Senate To Think Twice Before Weakening $9.4 Billion Rescissions Package

July 14, 2025
DOJ Fires 20 Employees Who Worked With Jack Smith On Trump Prosecutions

DOJ Fires 20 Employees Who Worked With Jack Smith On Trump Prosecutions

July 14, 2025
Liberals Marked Anniversary Of Trump Shooting By Pushing Wild Conspiracies On Their Favorite Platform

Liberals Marked Anniversary Of Trump Shooting By Pushing Wild Conspiracies On Their Favorite Platform

July 14, 2025
  • Donald Trump
  • State of the Union
  • Elon Musk
  • Tariffs
  • Congress
  • Faith
  • Immigration
Tuesday, July 15, 2025
  • Login
IJR
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls
No Result
View All Result
IJR
No Result
View All Result
Home News

Merck Anti-COVID Pill Will Not Be Added to India's National Treatment Protocol

by Western Journal
January 9, 2022 at 4:05 pm
in News
240 12
0
Merck Anti-COVID Pill Will Not Be Added to India's National Treatment Protocol
491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

One of India’s top health officials made major news last week with an announcement about safety concerns regarding an experimental treatment for COVID-19.

Director-General of the Indian Council of Medical Research Balram Bhargava used a news conference Wednesday to say the pharmaceutical giant Merck’s experimental COVID-19 pill, known as molnupiravir, will not be added to the country’s national treatment protocol, according to The Economic Times.

He cited the “major safety concerns” surrounding this pill for this decision, according to Reuters, including the potential to cause birth defects — technically known as teratogenicity — potential DNA damage — known as multagenicity — and other problems.

India says safety concerns restricting use of Merck COVID pill https://t.co/R9O9LvAN6f pic.twitter.com/JR9VUueMdV

— Reuters (@Reuters) January 5, 2022

“It can cause teratogenicity, mutagenicity and it also can cause cartilage damage and be damaging to muscles,” Bhargava said, according to Reuters.

“More importantly, contraception will have to be used for three months if this drug is given because the child born could be problematic with teratogenic influences.”

“The [World Health Organization] WHO has not included it, the UK has not included it as of now,” he noted.

“As of now, the current recommendation stands that it is not part of the national task force treatment.”

Bhargava added that the Drugs Controller General of India approved molnupiravir for emergency use in December.

Reuters reported that drugs in the same class as molnupiravir have been associated with birth defects in animal studies.

Yet, the news agency pointed out Merck’s claims that similar studies of this drug, “for longer [periods of time] and at higher doses than used in humans, show that it does not cause birth defects or cancer.”

Meanhwhile, the FDA has granted emergency use authorization to the pill in the U.S, according to Reuters.

“The pill is not recommended for use during pregnancy,” Reuters noted.

The article also reported that the FDA “advised that men of reproductive potential use a reliable method of birth control during treatment with molnupiravir, and for at least three months after the final dose.”

The FDA’s decision came a day after giving “broader go-ahead” to a Pfizer pill to fight the coronavirus, Reuters reported.

“Pfizer’s antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company’s clinical trial,” Reuters reported. “Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.”

The pill was approved for those 12 and older at risk of serious illness.

This article appeared originally on The Western Journal.

Tags: CoronavirusFood and Drug Administration FDAIndiaWorld Health Organization WHO
Share196Tweet123
Western Journal

Western Journal

Advertisements

Top Stories June 10th
Top Stories June 7th
Top Stories June 6th
Top Stories June 3rd
Top Stories May 30th
Top Stories May 29th
Top Stories May 24th
Top Stories May 23rd
Top Stories May 21st
Top Stories May 17th

Join Over 6M Subscribers

We’re organizing an online community to elevate trusted voices on all sides so that you can be fully informed.





IJR

    Copyright © 2024 IJR

Trusted Voices On All Sides

  • About Us
  • GDPR Privacy Policy
  • Terms of Service
  • Editorial Standards & Corrections Policy
  • Subscribe to IJR

Follow Us

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls

    Copyright © 2024 IJR

Top Stories June 10th Top Stories June 7th Top Stories June 6th Top Stories June 3rd Top Stories May 30th Top Stories May 29th Top Stories May 24th Top Stories May 23rd Top Stories May 21st Top Stories May 17th